• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

More Follow-Up Data from the Estrogen vs Lubricant RCT

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • RCTs have shown that vaginal estrogen creams and tablets, prasterone and ospemifene will provide relief from postmenopausal vaginal atrophy symptoms, but few studies have looked at sexual health and quality of life issues
  • Diem et al. (Menopause 2018) compared the efficacy of vaginal estradiol tablets and vaginal moisturizer to treat menopause-related quality of life and mood in women with vulvovaginal symptoms

METHODS:

  • Secondary data analysis of a 12-week, double-blind, placebo-controlled randomized trial (RCT)
  • Previous primary results on sexual function and decrease in severity of most bothersome symptoms were recently reported in JAMA Int Med (see summary below in ‘Related ObG Topics’)
  • Participants: Patients with moderate to severe symptoms of vulvovaginal itching, pain, dryness, irritation, or pain with penetration
    • Age 45 to 70 years, at least 2 years since last menses, report of at least 1 moderate to severe symptom at least weekly within the past 30 days or
    • Pain with penetration at least once monthly
  • Women were randomized to
    • 10 µg estradiol tablet plus placebo gel
    • vaginal moisturizer plus placebo tablet
    • dual placebo
  • Tablets were daily for 2 weeks then twice weekly for remaining 10 weeks
  • Vaginal gel was used every 3 days for 12 weeks
  • The Menopause-Specific Quality of Life (MENQOL) questionnaire was used to assess changes in quality of life
  • Evaluated specifically
    • Depressive symptoms as measured by Patient Health Questionnaire 8
    • Anxiety symptoms as measure by the Generalized Anxiety Disorder (GAD-7)

RESULTS:

  • Vaginal estradiol resulted in a greater improvement in total MENQOL scores, compared to dual placebo
    • Mean difference between arms -0.3 at 12 weeks; 95% CI, -0.5, 0.0; P = 0.01
  • A favorable group mean difference was observed for vaginal estradiol for MENQOL sexual function domain
    • -0.4 at 12 weeks; 95% CI -1.0, 0.1; P = 0.005
    • A favorable group mean difference for vaginal estrogen was not observed in any of the other domains
  • Treatment with vaginal moisturizer did not provide greater improvement compared to placebo in total MENQOL scores or any MENQOL domains
    • Mean difference 0.2 at 12 weeks; 95% CI -0.1, 0.4; P = 0.38
  • Neither treatment group showed improvement compared with placebo in the Patient Health Questionnaire 8 or Generalized Anxiety Disorder Questionnaire

CONCLUSION:

  • Treatment with low-dose vaginal estradiol modestly improved menopause-related quality of life and sexual function domain scores in postmenopausal women with moderate-severe vulvovaginal symptoms
  • Effect on MENQOL score was similar to low-dose oral 17-beta estradiol 0.5mg/day noted in a previous study
  • The previous paper that reported on this study did not find a significant difference in sexual function using Female Sexual Function Index (FSFI) as the primary measuring tool
    • FSFI is much more detailed, while MENQOL asks three questions but focuses on whether a woman is bothered by a decrease in sexual deire, vaginal dryness during intercourse and avoiding intimacy
  • The authors conclude that “multiple approaches to measuring sexual QOL are needed”

Learn More – Primary Sources:

Effects of vaginal estradiol tablets and moisturizer on menopause-specific quality of life and mood in healthy postmenopausal women with vaginal symptoms: a randomized clinical trial.

image_pdfFavoriteLoadingFavorite

< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

What and When to Tell Patients About Lubricants?
Prasterone for Vulvovaginal Atrophy – What is it and How to Prescribe
Genitourinary Syndrome of Menopause: New Name, Old Problem
Vaginal Moisturizers vs Vaginal Estradiol for Postmenopausal Vulvovaginal Symptoms

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site